Laura Arranz

Santa Cruz De Tenerife, CN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Journal: Alimentary pharmacology & therapeutics

Published: March 14, 2026

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Journal: Therapeutic advances in gastroenterology

Published: January 28, 2026

Hematological Composite Scores in Patients with Inflammatory Bowel Disease.

Hematological Composite Scores in Patients with Inflammatory Bowel Disease.

Journal: Journal of clinical medicine

Published: October 29, 2023

Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.

Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.

Journal: Journal of Crohn's & colitis

Published: July 31, 2023

Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.

Performance of Screening Strategies for Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease: Results from the ENEIDA Registry of GETECCU.

Journal: Journal of clinical medicine

Published: May 25, 2022

Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease.

Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease.

Journal: Clinical and translational gastroenterology

Published: November 01, 2021

Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.

Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection.

Journal: Gastroenterologia y hepatologia

Published: July 30, 2021

QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease.

QRISK3 Performance in the Assessment of Cardiovascular Risk in Patients with Inflammatory Bowel Disease.

Journal: Journal of clinical medicine

Published: July 28, 2021

Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease.

Insulin Resistance Is Not Increased in Inflammatory Bowel Disease Patients but Is Related to Non-Alcoholic Fatty Liver Disease.

Journal: Journal of clinical medicine

Published: June 27, 2021

Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.

Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry.

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Published: May 11, 2021

Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk.

Carotid Plaque Assessment Reclassifies Patients with Inflammatory Bowel Disease into Very-High Cardiovascular Risk.

Journal: Journal of clinical medicine

Published: March 13, 2021

Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.

Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.

Journal: United European gastroenterology journal

Published: July 30, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026